AGC to acquire Molmed for $267m.

AGC, a global contract development and manufacturing organization, offered to acquire Molmed, a biotechnology company, for $267m. AGC offered $0.577 per Molmed share, the equivalent of a premium of 110.3% compared to the stock’s closing price on March 16.